Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Over 1 billion people, including 500 million children, in the poorest regions of the world, are affected by neglected diseases that debilitate, disfigure or kill.

DNDi’s research and development approach is driven by the real day-to-day needs of patients and healthcare providers.

By connecting public and private partners, DNDi synergizes expertise and capitalizes upon the best science. 

DNDi also works to strengthen the health R&D field in the countries where the diseases occur in order to reinforce capacities for sustainable change.

Major progress has been made with six new treatments made available since the creation of DNDi, in 2003. However, major breakthroughs are still needed to treat neglected patients: Entirely new, affordable, and adapted drugs will change the lives of millions of people.


Finding a Cure for Kala Azar

AlJazeera's The Cure travels travels to Japan, Switzerland and Ethiopia to explore how big pharmaceutical companies are being mobilised by DNDi in a new global initiative to find and fast-track a cure for kala-azar. More

Close-up on Chagas Disease

For Juan Bautista Corzo Veloza, a 53 year old, father of three, life is not the same since that day in January 2013 when a stroke left him "dead for three days," he says. More

DNDi and MSF Access Campaign Directors answer questions on Reddit AMA

Bernard Pécoul and Manica Balasegaram answered questions on global health R&D funding on a PLOS Reddit Science AMA. More

DNDi hands over malaria programme to MMV

MMV and DNDi have agreed that the ASAQ and ASMQ products developed by DNDi and its partners will now be managed by the MMV Access and Product Management team. More

NTD Drug Discovery Booster

The NTD Drug Discovery Booster aims to speed up and cut the cost of finding new treatments for Leishmaniasis and Chagas Disease. The project brings together DNDi, Eisai, Shionogi, Takeda Pharmaceutical, and AstraZeneca. More



July 30 - August 2, 2015
11th Liver Update 2015
Selangor, Malaysia
DND will be presenting in a plenary and a symposium on hepatitis C.

August 10-13, 2015
1st ICC Leish
International Conference on Cutaneous Leishmaniasis

Manaus, Brazil
DNDi 's Head of Cutaneous Leishmaniasis will be giving an oral and a poster presentation.

September 6-10, 2015
9th European Congress on Tropical Medicine and International Health
Basel, Switzerland
DNDi will be presenting in symposia and poster sessions on visceral leishmaniasis, open source drug discovery, Chagas disease, helminth infections, sleeping sickness, and mycetoma.

See all events



DNDi Model Paper
DNDi has issued a report that explores the lessons learned from a decade of R&D of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model. Read more


Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License